ABIONYX Pharma Announces Its 2022 Full-year Financial Results

Regulatory News:

ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announced its 2022 financial annual results as approved by the full Board of Directors and an update on the activity to date. The audit procedures on the consolidated accounts have been completed. The certification report will be issued after completion of the procedures required for the filing of the universal registration document.

Selected financial information

(as of December 31, 2022/Consolidated financial statements under IFRS)

M€	2022	2021
Revenues	5.3	0.7
Cost of goods and services sold	(4.6)	(0.4)
R&D expenditure	(1.1)	(3.8)
Administrative and commercial expenses	(3.7)	(2.3)
Other income and expenses	0	(0.1)
Operating Income	(4.1)	(5.9)
Financial income	0.2	0.3
Financial expenses	(0.3)	(0.2)
Financial result	(0.1)	0.1
Net income	(4.2)	(5.8)
Net cash flow from operating activities	(3.4)	(6.7)
Net cash used in investing activities	(0.2)	1.3
Net cash flow from financing activities	(0.2)